←Back to Cancer Screening

Best Cancer Screening Tests in 2026

Multi-cancer early detection (MCED) tests represent a paradigm shift in cancer screening. Instead of testing for one cancer at a time, these blood tests scan for signals from dozens of cancer types simultaneously. We compared ten cancer screening services, from established tests like Cologuard for colon cancer to new liquid biopsies like Galleri that screen for 50+ cancers. Prices range from $79 for single-cancer tests to $949 for comprehensive MCED panels. The technology is advancing rapidly, but not all tests have equal clinical validation. Some have FDA approval while others operate as laboratory-developed tests. This guide explains what current tests can and cannot detect, and who should consider screening beyond standard guidelines.

6 Picks ReviewedUpdated Jan 2026

Quick Comparison

At-a-glance comparison of our top picks. Updated Jan 2026

RankProviderPriceBest For
1Galleri by GRAIL $949 High-risk individuals wanting comprehensive screening
2Shield by Guardant $1495 Adults 45+ wanting non-invasive CRC screening
3Cologuard by Exact Sciences $599 Adults 45+ preferring home collection for CRC screening
4Signatera by Natera $Variable Cancer patients monitoring for recurrence
5Prenetics CIRCLE $Varies Those wanting affordable multi-cancer screening
6Freenome $Variable Those interested in emerging MCED technology

Top Picks

Detailed breakdown of each recommended option with pros, cons, and who it's best for.

1

Galleri by GRAIL

Best for:High-risk individuals wanting comprehensive screening
$949
Detects a signal shared by 50+ cancers. GRAIL now leads with >70% sensitivity across the 12 cancers causing two-thirds of US cancer deaths (pancreatic 83.7%, liver/bile duct 93.5%, ovary 83.1%). PPV ~62%, cancer signal origin accuracy 93.4%. List $949;self-pay $799 via participating providers. Not covered by Medicare or most plans;assistance up to $350 off at or below 400% FPL. PMA submitted January 2026 with an FDA advisory committee meeting set for 23 September 2026.
2

Shield by Guardant

Best for:Adults 45+ wanting non-invasive CRC screening
$1495
First FDA-approved blood test for primary colorectal cancer screening. $1,495 cash pay;most insured patients pay $0. Medicare covered, UnitedHealthcare coverage added, VA Community Care covered. ADLT status from CMS. Detects only 13% of advanced adenomas. Note:Guardant's separate Shield MCD multi-cancer test is NOT FDA approved and is a different product at a different price.
3

Cologuard by Exact Sciences

Best for:Adults 45+ preferring home collection for CRC screening
$599
Cologuard Plus is the current flagship:95% sensitivity for Stage I-IV CRC, 94% specificity, detects 43% of advanced precancerous lesions. Self-pay $599. $0 for eligible Medicare Part B members 45-85 and ACA-eligible patients 45-75;free at or below 400% FPL. The older original Cologuard (92%/87%, $649) is a separate legacy product. Exact Sciences was acquired by Abbott, closing 23 March 2026.
4

Signatera by Natera

Best for:Cancer patients monitoring for recurrence
$Variable
Not for initial detection - monitors known cancer patients for molecular residual disease. Tumor-informed, 64 clonal variants, ultra-deep sequencing to 350,000x. Medicare covered across colorectal, breast, bladder, lung, ovarian and pan-cancer ICI monitoring. The general MRD test is a CLIA laboratory-developed test, NOT FDA approved;only Signatera CDx holds FDA approval, as a companion diagnostic in muscle-invasive bladder cancer. CMS ADLT rate is $3,500 per assay per blood draw - this is a serial test, so annual cost depends on draw frequency.
5

Prenetics CIRCLE

Best for:Those wanting affordable multi-cancer screening
$Varies
IMPORTANT:this is a hereditary risk test, not active cancer detection. CircleDNA is a consumer whole-exome saliva test whose Cancer Screening Report assesses inherited predisposition across 35+ cancers - it does not detect existing cancer. Hong Kong based (Prenetics Global, NASDAQ:PRE);pricing is served in HKD and varies by region. Prenetics'actual blood-based multi-cancer test is Presight, via the Insighta joint venture with Prof. Dennis Lo (lung and liver today;Presight One for 10+ cancers targeted for 2027).
6

Freenome

Best for:Those interested in emerging MCED technology
$Variable
SimpleScreen CRC won FDA approval on 27 July 2026 for average-risk adults 45+:81.1% CRC sensitivity, 90.4% specificity, 13.7% for advanced precancerous lesions. Blood-based cfDNA with AI/ML, validated in PREEMPT CRC (48,000+ participants). Abbott will exclusively commercialise it in the US from autumn 2026, so pricing is not yet announced. Included in the updated ACS colorectal screening guideline.

How We Chose These Picks

We evaluated cancer screening tests on detection sensitivity (what percentage of cancers does the test find), specificity and false positive rates (false alarms cause anxiety and unnecessary procedures), cancer types covered (single cancer versus multi-cancer panels), clinical validation (FDA approval, peer-reviewed studies, and ongoing trials), and actionability of results (what happens after a positive finding). We reviewed published clinical trial data for each test and interviewed oncologists about which tests they recommend or discourage. Tests with strong clinical evidence and clear follow-up protocols scored highest. We heavily weighted false positive rates since the psychological and medical costs of false alarms are significant. We also considered whether positive results lead to earlier treatment that improves outcomes, as detection without survival benefit has limited value. Pricing verified January 2026.

Frequently Asked Questions

What's the difference between Galleri and traditional cancer screening?

Traditional screening tests (mammograms, colonoscopies, PSA tests) look for one specific cancer each. Galleri analyzes cell-free DNA in blood to detect signals from 50+ cancer types, including many without standard screening tests. Galleri supplements rather than replaces traditional screening. Its strength is finding cancers that would otherwise be detected only after symptoms appear, often at later stages.

How accurate are multi-cancer early detection tests?

Galleri detects approximately 50% of stage 1-3 cancers across all types, with higher sensitivity for later-stage and certain aggressive cancers. Specificity is about 99.5%, meaning 0.5% false positive rate. For specific cancers, traditional screening may be more sensitive, but MCED catches cancers that lack any screening option. No test catches everything, and negative results don't guarantee you're cancer-free.

Who should consider multi-cancer screening tests?

People at elevated cancer risk due to age (50+), family history, or genetic predisposition may benefit most. Those with access to timely follow-up care get more value since positive results require additional testing. MCED tests are not recommended as the only screening approach since they complement but don't replace colonoscopy, mammography, and other proven screens. Cost and insurance coverage also factor into the decision.

What happens if a multi-cancer test is positive?

A positive result triggers additional diagnostic testing to locate and confirm the cancer. MCED tests predict the likely cancer origin, but imaging and potentially biopsy confirm the finding. This process may involve weeks of uncertainty and multiple appointments. Approximately 1-2% of positive results are false positives that don't find cancer after workup. Discuss the implications with your doctor before testing.

Are these tests covered by insurance?

Coverage varies significantly. Cologuard for colorectal screening is widely covered. Newer MCED tests like Galleri typically aren't covered by insurance or Medicare. Some employers and concierge medicine practices include them in health benefits. Prices range from $600-950 out of pocket. As clinical evidence accumulates, coverage is expected to expand over the next several years.

Ready to Get Started?

Compare all options and find the best fit for your health goals.

View All Cancer Screening Options

Important Disclaimer

This comparison is for informational purposes only and is not medical advice. Prices are based on January 2026 data and may vary. Consult with a healthcare provider before making health-related decisions.

Get monthly price updates &deals

We track pricing changes across 50+ health testing providers so you don't have to.

Free, once a month. No spam.